Radiation Oncology/Drugs/Concurrent chemo
|
Concurrent chemo-RT schedules
| Section | Site | Chemo | RT | Rationale |
|---|---|---|---|---|
| CNS | Glioblastoma: adjuvant | Temozolomide 75 mg/m2 daily | 46 + 14 = 60 Gy | EORTC 26981 |
| GI | Esophagus: neoadjuvant | Cisplatin 100 mg/m2 D1, D29 + C.I. 5-FU 1000 mg/m2 D1-4, D29-32 | 45 + 5.4 = 50.4 Gy | CALGB 9781 |
| GI | Gastric: adjuvant | Bolus 5-FU 400 mg/m2 + LV 20 mg/m2 first 4 and last 3 days of RT | 45 Gy | INT 0116 |
| GI | Pancreas: adjuvant | C.I. 5-FU 250 mg/m2 daily | 45 + 5.4 = 50.4 Gy | NCCN |
| GI | Rectum: neoadjuvant | C.I. 5-FU 225 mg/m2 daily | 45 + 5.4 = 50.4 Gy | NCCN |
| GI | Rectum: adjuvant | C.I. 5-FU 225 mg/m2 daily | 45 + 9.0 = 54 Gy | NCCN |
| GI | Anal: definitive | C.I. 5-FU 1000 mg/m2 D1-4, D29-32; mitomycin 10 mg/m2 D1 and D29 | 30.6 + 14.4 +/- 5.4-15 Gy = 45-59 Gy | RTOG 98-11 |
| GU | Prostate: definitive | Lupron 7.5 mg IM every month and flutamide 250 mg TID | 70 (to 80) Gy | Harvard |
| GYN | Cervix: adjuvant | Cisplatin 70 mg/m2 and C.I. 5-FU 1000 mg/m2 Q3W | 49.3 Gy | GOG 109 |
| GYN | Cervix: definitive | Cisplatin 40 mg/m2 weekly | 80-85 Gy Point A | GOG 120 |
| H&N | Head & Neck: adjuvant | Cisplatin 100 mg/m2 Q3W | 60-66 Gy | RTOG 95-01 |
| Peds | Medulloblastoma: adjuvant | Vincristine 1.5 mg/m2 weekly | 55. 8 Gy | CCG A9961 |
| Thorax | NSCLC: neoadjuvant | Cisplatin 50 mg/m2 D1,8,29,36 and etoposide 50 mg/m2 D1-5,29-33 | 45 Gy | INT-0139 |
| Thorax | NSCLC: definitive | Cisplatin 50 mg/m2 D1,8,29,36 and etoposide 50 mg/m2 D1-5,29-33 | 66 Gy | NCCN |
| Thorax | SCLC: definitive | Cisplatin 60 mg/m2 D1 and etoposide 120 mg/m2 D1-3 Q3W | 45 Gy BID | INT-0096 |